Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ASP2138 plus chemotherapy with or without pembrolizumab for first-line HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20263362Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ASP2138 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Aug 2026; status: active.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20263362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263362.